Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12787584 | 1.00 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL17147302 | 0.85 | CHRM2 (0.78) | CHRM2CHRM3ADRA1AADRA1B | |
| SCHEMBL1043522 | 0.83 | CHRM2 (0.71) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1043555 | 0.83 | CHRM2 (1.00) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| Bromide SCHEMBL6649504 | 0.81 | CHRM2 (0.97) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| Bromide SCHEMBL194843 | 0.80 | CHRM2 (0.93) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1042163 | 0.80 | CHRM2 (0.65) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL1042941 | 0.80 | CHRM2 (0.65) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL12787585 | 0.80 | CHRM2 (0.65) | CHRM2CHRM3ADRA1AADRA1BHTR2A | |
| SCHEMBL18179697 | 0.79 | CHRM2 (0.69) | CHRM2CHRM3ADRA1AADRA1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2020-12-08 | — | — | US | disclosed |
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | THE GENERAL HOSPITAL CORPORATION (US) | 2020-03-03 | — | — | US | disclosed |
| US-20150283113-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-20150283113-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-9005578-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | FLUOROPHARMA, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2015-04-09 | — | — | US | disclosed |
| WO-2014066318-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | FLUOROPHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8450466-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPTIAL CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2011-03-10 | — | — | US | disclosed |
| EP-2268647-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117728-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576171-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | CHRM2 67/4885CHRM3 81/4885ADRA1A 246/4885 |
| US-11801316-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | CHRM2 89/4885CHRM3 98/4885ADRA1A 250/4885 |
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | CHRM2 276/4885CHRM3 244/4885ADRA1A 354/4885 |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | APP, PSEN1, PSEN2 | CHRM2 276/4885CHRM3 244/4885ADRA1A 354/4885 |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | CHRM2 276/4885CHRM3 244/4885ADRA1A 354/4885 |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | CHRM2 276/4885CHRM3 244/4885ADRA1A 354/4885 |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | CHRM2 276/4885CHRM3 244/4885ADRA1A 354/4885 |
| US-20150283113-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
| US-11666669-B2 | Cromolyn derivatives and related methods of imaging and treatment | PSEN1, PSEN2, CROCC | CHRM2 99/4885CHRM3 107/4885ADRA1A 254/4885 |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | CHRM2 1187/4885CHRM3 1391/4885ADRA1A 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.